SALT
LAKE CITY, Nov. 29, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that Co-Diagnostics will be presenting at the Piper
Sandler 35th Annual Healthcare Conference in
New York City, New York on November
30, 2023.
The presentation will be conducted by Co-Diagnostics CEO
Dwight Egan at 12:10 PM EST and will include a discussion of
Company progress on its forthcoming Co-Dx™ at-home and
point-of-care PCR platform*.
The Company will also be participating in one-on-one meetings
with institutional investors, which can be arranged via
representatives of Piper Sandler.
*The Co-Dx PCR at-home and point-of-care platform (including
the PCR Home™, PCR Pro™, mobile app, and all associated test kits)
is subject to review by the FDA and/or other regulatory bodies and
is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-in-new-york-city-on-november-30-2023-302000365.html
SOURCE Co-Diagnostics